CLASS II Device recall · Reported 8 Sep 2021 · FDA Enforcement Report

CareStart Covid-19 Antigen Rapid Diagnostic Test recalled

Versea Diagnostics is recalling CareStart Covid-19 Antigen Rapid Diagnostic Test for the detection of Sars-CoV-2 Antigen, distributed nationwide in the US. The recall was initiated on 27 Jul 2021 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesall lot codes
Quantity recalled563,290 in total

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-2407-2021
FDA event ID
88429
Recalling firm
Versea Diagnostics, Tampa, FL
Classification
Class II
Status
Terminated
Recall initiated
27 Jul 2021
FDA classified
2 Sep 2021
Reported
8 Sep 2021
Type
Voluntary: Firm initiated
Customers notified by
E-Mail
Reason category
Other Reasons

Timeline

27 Jul 2021Recall initiated by company
2 Sep 2021Classified by FDA+37 days
8 Sep 2021Published in enforcement report+6 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Products may have been distributed to customers other than laboratories certified under the Clinical Laboratory Improvement Amendments as stipulated in the Emergency Use Authorization.

Product as listed by the FDA

CareStart COVID-19 Antigen Rapid Diagnostic Test for the detection of SARS-CoV-2 Antigen Qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in nasopharyngeal or anterior nasal swab specimens directly collected from individuals suspected of COVID-19 by their healthcare provider within five days of symptom onset, or from individuals without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two or three days with at least 24 hours and no more than 48 hours between tests. (CLIA Waived Laboratories)

Where it was distributed

US Nationwide Distribution: AL, AZ, CA, CO, CT, FL, GA, IL, KS, OH, OK, MA, MD, MI, NC, NJ, NY, PA, SC, TX, VA, and WA.

Nationwide AlabamaArizonaCaliforniaColoradoConnecticutFloridaGeorgiaIllinoisKansasMassachusettsMarylandMichiganNorth CarolinaNew JerseyNew YorkOhioOklahomaPennsylvaniaSouth CarolinaTexas

Questions about this recall

Is CareStart Covid-19 Antigen Rapid Diagnostic Test for the detection of Sars-CoV-2 Antigen recalled?

Yes. Versea Diagnostics recalled CareStart Covid-19 Antigen Rapid Diagnostic Test for the detection of Sars-CoV-2 Antigen on 27 Jul 2021. The recall is Class II and its status is Terminated. Recall number Z-2407-2021.

Why was it recalled?

Products may have been distributed to customers other than laboratories certified under the Clinical Laboratory Improvement Amendments as stipulated in the Emergency Use Authorization.

Which lots are affected?

all lot codes

Where was it sold?

US Nationwide Distribution: AL, AZ, CA, CO, CT, FL, GA, IL, KS, OH, OK, MA, MD, MI, NC, NJ, NY, PA, SC, TX, VA, and WA.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Versea Diagnostics

All 4

Other Test Kits & Diagnostics recalls

All 2,656